Synthesis and evaluation of potent and selective β3 adrenergic receptor agonists containing heterobiaryl carboxylic acids

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 16, 2007, Pages 4670-4677

  Shearer, Barry G ^a   Chao, Esther Y ^a   Uehling, David E ^a   Deaton, David N ^a   Cowan, Conrad ^a   Sherman, Bryan W ^a   Milliken, Tula ^a   Faison, Walter ^a   Brown, Kathleen ^a   Adkison, Kimberly K ^a   Lee, Frank ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

3 Adrenergic receptor; Agonist; Diabetes; Selective

Indexed keywords

2 (4 AMINOPHENYL)OXAZOLE 4 CARBOXYLIC ACID; 2 ANILINO 3 FURANCARBOXYLIC ESTER; 2 ANILINO 3 THIOPHENECARBOXYLIC ESTER; 2 ANILINO 4 OXAZOLECARBOXYLIC ESTER; 2 ANILINO 4 THIAZOLECARBOXYLIC ESTER; 2 ARYLTHIAZOLE 4 CARBOXYLIC ACID; 5 (4 AMINOPHENYL)OXAZOLE 4 CARBOXYLIC ACID; 5 ANILINO 4 OXAZOLECARBOXYLIC ESTER; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA3 ADRENERGIC RECEPTOR STIMULATING AGENT; CARBOXYLIC ACID DERIVATIVE; ESTER DERIVATIVE; FURAN DERIVATIVE; OXAZOLE DERIVATIVE; PHENETHANOLAMINE BETA3 ADRENERGIC RECEPTOR STIMULATING AGENT; PHENYLETHANOLAMINE DERIVATIVE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

BINDING SITES; CARBOXYLIC ACIDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECEPTORS, ADRENERGIC, BETA-3; STRUCTURE-ACTIVITY RELATIONSHIP;

RODENTIA;

EID: 34447336958     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.05.069     Document Type: Article

References (33)

1. Himms-Hagen J., and Danforth Jr. E. Curr. Opin. Endocrin. Diabetes 3 (1996) 59
2. Collins P., and Williams G. J. Clin. Pharmacol. 51 (2001) 13
3. Weyer C., Gautier J.F., and Danforth Jr. E. Diabetes Metab. 25 (1999) 11
4. Kordik C.P., and Reitz A.B. J. Med. Chem. 42 (1998) 181
5. Weber A.E. Ann. Rep. Med. Chem. 33 (1998) 193
6. Largis E.E., Burns M.G., Muenkel H.A., Dolan J.A., and Claus T.H. Drug Dev. Res. 32 (1994) 69
7. Bloom J.D., Dutia M.D., Johnson B.D., Wissner A., Burns M.G., Largis E.E., Dolan J.A., and Claus T.H. J. Med. Chem. 35 (1992) 3081
8. Hollenga C., Brouwer C., and Zaagsma J. Eur. J. Pharmacol. 200 (1991) 325
9. Wilson C., Wilson S., Piercy V., Sennitt M.V., and Arch J.R.S. Eur. J. Pharmacol. 100 (1984) 309
10. Liggett S.B. Mol. Pharmacol. 42 (1992) 634
11. Weyer C., Tataranni P.A., Snitker S., Danforth Jr. E., and Ravussin E. Diabetes 47 (1998) 1555
12. Lipworth B.J. Br. J. Clin. Pharmacol. 42 (1996) 291
13. Emorine L.J., Marullo S., Briend-Sutren M.-M., Patey G., Tate K., Delavier-Klutchko C., and Strosberg A.D. Science 245 (1989) 1118
14. Granneman J.G., Lahners K.N., and Chaudhry A. Mol. Pharmacol. 40 (1991) 895
15. Nahamias C., Blin N., Elalouf J.-M., Mattei M.G., Strosberg A.D., and Emorine L.J. EMBO J. 10 (1991) 3721
16. Strosberg A.D., and Pietri-Rouxel F. Trends Pharm. Sci. 17 (1996) 373
17. Washburn W.N., Sher P.M., Poss K.M., Girotra R.N., McCann P.J., Gavai A.V., Mikkilineni A.B., Mathur A., Cheng P., Dejneka T.C., Sun C.Q., Wang T.C., Harper T.W., Russell A.D., Slusarchyk D.A., Skwish S., Allen G.T., Hillyer D.E., Frohlich B.H., Abboa-Offei B.E., Cap M., Waldron T.L., George R.J., Tesfamariam B., Ciosek Jr. C.P., Ryono D., Young D.A., Dickinson K.E., Seymour A.A., Arbeeny C.M., and Gregg R.E. Bioorg. Med. Chem. Lett. 11 (2001) 3035
18. Fisher M.H., Amend A.M., Bach T.J., Barker J.M., Brady E.J., Candelore M.R., Carroll D., Cascieri M.A., Chiu S.-H.L., Deng L., Forrest M.J., Hegarty-Friscino B., Guan X.-M., Hom G.J., Hutchins J.E., Kelly L.J., Mathvink R.J., Metzger J.M., Miller R.R., Ok H.O., Parmee E.R., Saperstein R., Strader C.D., Stearns R.A., Thompson G.M., Tota L., Vicario P.P., Weber A.E., Woods J.W., Wyvratt M.J., Zafian P.T., and MacIntyre D.E. J. Clin. Invest. 101 (1998) 2387
19. Shih T.L., Candelore M.R., Cascieri M.A., Chiu S.-H.L., Colwell L.F., Deng L., Feeney W.P., Forrest M.J., Hom G.J., MacIntyre D.E., Miller R.R., Stearns R.A., Strader C.D., Tota L., Wyvratt M.J., Fisher M.H., and Weber A.E. Bioorg. Med. Chem. Lett. 9 (1999) 1251
20. Uehling D.E., Donaldson K.H., Deaton D.N., Hyman C.E., Sugg E.E., Barrett D.G., Hughes R.G., Reitter B., Adkison K.K., Lancaster M.E., Lee F., Hart R., Paulik M.A., Sherman B.W., True T., and Cowan C. J. Med. Chem. 45 (2002) 567
21. Foxton, M.W. WO9533724, 1995.
22. Uehling D.E., Shearer B.G., Donaldson K.H., Chao E.Y., Deaton D.N., Adkison K.K., Brown K.K., Cariello N.F., Faison W.L., Lancaster M.E., Lin J., Hart R., Milliken T.O., Paulik M.A., Sherman B.W., Sugg E.E., and Cowan C. J. Med. Chem. 49 (2006) 2758
23. Sher P.M., Mathur A., Fisher L.G., Wu G., Skwish S., Michel I.M., Seiler S.M., and Dickinson K.E.J. Bioorg. Med. Chem. Lett. 7 (1997) 1583
24. Moody C.J., Swann E., Houlbrook S., Stephens M.A., and Stratford I.J. J. Med. Chem. 38 (1995) 1039
25. Bellamy F.D., and Ou K. Tetrahedron Lett. 25 (1984) 839
26. Suzuki M., Iwasaki T., Matsumoto K., and Okumura K. Syn. Commun. 2 (1972) 237
27. Jurasek A., Berecinova D., Cakrt M., Dandarova M., Friedl Z., Stetinova J., and Kovac J. Collect. Czech. Chem. Commun. 54 (1989) 215
28. Granneman J.G., Lahners K.N., and Rao D.D. Mol. Pharmacol. 42 (1992) 964
29. Oriowo M.A., Chapman H., Kirkham D.M., Sennitt M.V., Ruffolo Jr. R.R., and Cawthorne M.A. J. Pharmacol. Exp. Ther. 277 (1996) 22
30. Weber A.E., Mathvink R.J., Perkins L., Hutchins J.E., Candelore M.R., Tota L., Strader C.D., Wyvratt M.J., and Fisher M.H. Bioorg. Med. Chem. Lett. 8 (1998) 1101
31. 4Cl) C, H, N.
32. Compound 49 was administered twice daily (BID) by oral gavage to male db/db mice (10 mice/group; 60 days of age at onset of dosing) for 14 days. The reconstitution vehicle for the in vivo studies was 0.025 M methanesulfonic acid. Dosing solutions were prepared fresh daily. Prior to the start of dosing, 10 mice were anesthetized and exsanguinated by cardiac puncture for baseline measurements (Day 0 predose values) of postprandial glucose, glycosylated hemoglobin, and insulin. Subsequently, on days 7 and 14 of dosing, mice from each dose group were sacrificed and blood samples for glucose measurements were obtained. Body weights were measured throughout the study and there were no significant effects of any of the compounds on body weight gain in these studies. All serum biochemical measurements were made using an ILAB600 automated chemistry Analyzer (Instrumentation Laboratories).
33. Arbeeny C.M., Myers D.S., Hillyer D.E., and Bergquist K.E. Am. J. Physiol. 268 (1995) E678